Innate Pharma reports first half 2021 financial results and business update

NEXT STORY
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
PREV STORY
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

author_avatar
NASDAQ Market News

Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence

NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a ...

author_avatar
NASDAQ Market News

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

author_avatar
NASDAQ Market News